TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6430053
Drug: Sublingual NTG
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual NTG (positive control)
Study: 27447428
Drug: VEL015 (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEL015 (sodium selenate) 10 mg tds (n=20)
Study: 24517114
Drug: Teduglutide 4
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide 4 mg once daily for 10 days
Study: 20561625
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g glucose control
Study: 17318839
Drug: Sumanirole, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumanirole, 1 to 16 mg/day
Study: 17318839
Drug: Ropinirole, 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole, 0.75 to 24 mg/day
Study: 15680855
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch solution
Study: 10839469
Drug: Reboxetine 2-8
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 2-8 mg/day
Study: 1617494
Drug: Disodium monofluorophosphate-calcium
Normalized name: calcium monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium monofluorophosphate-calcium carbonate (MFP-Ca) 100 mg with breakfast
Study: 1617494
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (NaF) 25 mg fasting
Study: 6393670
Drug: NPH biosynthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH biosynthetic human insulin
Study: 6393670
Drug: NPH pork
Normalized name: Iletin II NPH Pork
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH pork insulin
Study: 31834152
Drug: Office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence/accommodative therapy for intermittent exotropia (60 minutes once per week for 12 weeks)
Study: 31834152
Drug: Office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence/accommodative therapy for intermittent exotropia
Study: 26896263
Drug: PCI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI with Drug-Eluting Stents (DES)
Study: 24658221
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol (0.6 g/kg for females, 0.7 g/kg for males)
Study: 24658221
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ethanol (1.2 g/kg for females, 1.4 g/kg for males)
Study: 15740541
Drug: Tenatoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenatoprazole 40 mg
Study: 11919405
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous sodium ferric gluconate (6.25-21.3 mg in every hemodialysis session)
Study: 11919405
Drug: Intermittent sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sodium ferric gluconate (62.5 mg every 1-4 weeks)
Study: 7717630
Drug: Nucleus 22
Normalized name: SUS SCROFA THALAMUS LATERAL GENICULATE NUCLEUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus 22 cochlear implant
Study: 7717630
Drug: Smith &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smith & Nephew Richards Ineraid cochlear implant
Study: 7717630
Drug: 3M/Vienna cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3M/Vienna cochlear implant
Study: 23043926
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention combined with Tagamet 800 mg per evening p.o.
Study: 23043926
Drug: Tagamet 800
Normalized name: Tagamet 800mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagamet 800 mg per evening p.o.
Study: 19938712
Drug: Modified gelatin
Normalized name: modified fluid gelatins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified gelatin solution ‐ Gelofusin
Study: 11588740
Drug: Inpatient rehabilitation
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient rehabilitation (therapeutical and neuromuscular exercises with occupational therapy with professional supervision)
Study: 9848512
Drug: Soy supplementation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplementation (60-g soy supplement containing 45 mg isoflavones) taken daily for 14 days
Study: 8079970
Drug: Dialysate magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate magnesium concentration of 0 mg/dL
Study: 8079970
Drug: Dialysate magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate magnesium concentration of 0.6 mg/dL
Study: 8079970
Drug: Dialysate magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate magnesium concentration of 1.8 mg/dL
Study: 2589846
Drug: Zidovudine syrup
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine syrup
Study: 2589846
Drug: Zidovudine solution
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine solution
Study: 2589846
Drug: Zidovudine capsule
Normalized name: Zidovudine Capsules
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine capsule
Study: 1039629
Drug: 50-minute class
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-minute class in acupuncture and Chinese medicine
Study: 28692467
Drug: Bolus-plus-infusion group
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus-plus-infusion group (tranexamic acid 1g infusion for 8 hours)
Study: 28692467
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (placebo infusion for 8 hours)
Study: 25941995
Drug: Sham insole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham insole treatment
Study: 21316752
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 mg on day 1 to 16 mg on days 3 to 7)
Study: 14610122
Drug: Topiramate at
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate at low plasma level (6 micromol/L [2 mg/L])
Study: 14610122
Drug: Topiramate at
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate at medium plasma level (31 micromol/L [10.5 mg/L])
Study: 14610122
Drug: Topiramate at
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate at high plasma level (56 micromol/L [19 mg/L])
Study: 10696124
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy leading to complete necrosis (CNWT)
Study: 8730245
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 750 mg t.d.s. for 2 weeks
Study: 8730245
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg t.d.s. plus amoxycillin 750 mg t.d.s. for 2 weeks
Study: 1420747
Drug: High enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: High enzyme preparation ('Pancrease HL', Cilag)
Study: 1420747
Drug: Standard pancreatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pancreatic enzyme supplement ('Creon', Duphar)
Study: 12355035
Drug: Intravenous blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous blockade of the glycoprotein IIb/IIIa receptor
Study: 12355035
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment duration
Study: 12355035
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of glycoprotein IIb/IIIa inhibitor
Study: 7642758
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control groups
Study: 2694315
Drug: 100 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg/kg of ivermectin
Study: 2694315
Drug: 150 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mcg/kg of ivermectin
Study: 2694315
Drug: 200 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg/kg of ivermectin
Study: 25917009
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) combined with Cognitive Behavioral Therapy for Depression (CBT-D)
Study: 25917009
Drug: Sleep Hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Hygiene (SH) control condition combined with Cognitive Behavioral Therapy for Depression (CBT-D)
Study: 20940691
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens (Permixon®) 320 mg daily for two months prior to surgery (G1)
Study: 10715308
Drug: Tirapazamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirapazamine plus cisplatin (390 mg/m2 infused over 2 hours followed 1 hour later by cisplatin 75 mg/m2 over 1 hour, every 3 weeks for a maximum of eight cycles)
Study: 10715308
Drug: Cisplatin alone
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin alone (75 mg/m2, every 3 weeks for a maximum of eight cycles)
Study: 1539786
Drug: Papaveretum followed
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum followed by paracetamol plus dextropropoxyphene orally
Study: 3904205
Drug: Gamma therapy
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma therapy with total focal dose of 90-120 Gy
Study: 29175357
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sodium nitrite (1 or 9.6mg)
Study: 29175357
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sodium nitrite (9.6mg)
Study: 16000283
Drug: 18F‐FDG PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F‐FDG PET after the first cycle of chemotherapy
Study: 16000283
Drug: 18F‐FDG PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F‐FDG PET after the second cycle of chemotherapy
Study: 16000283
Drug: 18F‐FDG PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F‐FDG PET for nonresponding lesions after the first cycle of chemotherapy
Study: 16000283
Drug: 18F‐FDG PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F‐FDG PET for nonresponding lesions after the second cycle of chemotherapy
Study: 12432319
Drug: Opioid analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics pro re nata (as needed)
Study: 12432319
Drug: Regularly scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly scheduled opioid analgesics
Study: 8565248
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal therapy (group 1)
Study: 25502841
Drug: Remimazolam (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.10 mg/kg)
Study: 25502841
Drug: Remimazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.15 mg/kg)
Study: 25502841
Drug: Remimazolam (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.20 mg/kg)
Study: 25502841
Drug: Remimazolam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (all doses)
Study: 21227735
Drug: 2 weekly
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weekly replacement lenses
Study: 21227735
Drug: Monthly replacement
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly replacement lenses
Study: 12390609
Drug: Multidisciplinary management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary management program (neurologist and physical therapist intake and discharge, 18 group-supervised exercise therapy sessions, 2 group stress management and relaxation therapy lectures, 1 group dietary lecture, and 2 massage therapy sessions)
Study: 9749162
Drug: Additional prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional prescription of beta-blocker
Study: 9749162
Drug: Additional prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional prescription of ACE-inhibitor
Study: 8156459
Drug: Spiramycin, 1,500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin, 1,500,000 international units, twice per day (IU, bid) for 14 days
Study: 8156459
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (visually identical)
Study: 2459514
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg once or twice daily)
Study: 2459514
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg twice daily)
Study: 26572551
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (group sessions)
Study: 25216143
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed level with the buccal crest (Group 0)
Study: 25216143
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed 1 mm apical to the buccal aspect of the alveolar crest (Group 1)
Study: 25216143
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed 2 mm apical to the buccal aspect of the alveolar crest (Group 2)
Study: 21035616
Drug: PMT-S (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMT-S (single instructional workshop followed by self-administration)
Study: 10206081
Drug: MPV-2213ad 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPV-2213ad 0.3 mg
Study: 10206081
Drug: MPV-2213ad 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPV-2213ad 3 mg
Study: 10206081
Drug: MPV-2213ad 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPV-2213ad 100 mg
Study: 729626
Drug: Indoramin 50
Normalized name: indoramin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 50 mg t.i.d.
Study: 31138224
Drug: Duloxetine 30/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30/60 mg once daily (QD)
Study: 31138224
Drug: Duloxetine 30/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30/60 mg QD
Study: 25380326
Drug: CO2 angiography-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 angiography-guided endovascular therapy (EVT)
Study: 16960168
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of black (0.1 g), green (0.1 g), and mulberry (1.0 g) teas with carbohydrate-containing meal (50 g carbohydrate as white rice, 10 g butter, and 0.2 g [13C]triolein)
Study: 16960168
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of black, green, and mulberry teas with lipid-containing meal (30 g olive oil and 0.2 g [13C]triolein)
Study: 12848875
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of AMI-I (GCT)
Study: 10783989
Drug: Radiotherapy (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (high-dose radiation)
Study: 10783989
Drug: Chemoradiation (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (combination of chemotherapy and radiation)
Study: 10783989
Drug: Multi-modality therapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modality therapy (combination of treatments)
Study: 8796164
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with 2% prilocaine
Study: 6233148
Drug: Piracetam (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (administered intravenously)
Study: 22180633
Drug: ANA 150
Normalized name: Ana-Lex
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANA 150 mg/day
Study: 22180633
Drug: ANA 20
Normalized name: Ginsana 200mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANA 20 mg/day
Study: 19906799
Drug: Seasonally adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonally adjusted 25(OH)D concentration <50 nmol/L
Study: 16129989
Drug: Tramadol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (mean dose 448 mg)
Study: 16129989
Drug: Amitriptyline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (mean dose 55 mg)
Study: 12006895
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg for the first 8 weeks, then increased by 20 mg every two weeks to a maximum of 60 mg/day)
Study: 25700621
Drug: DY-807f (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: DY-807f (360 mg)
Study: 25700621
Drug: DY-807f (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DY-807f (60 mg)
Study: 25700621
Drug: DY-807f (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: DY-807f (various doses: 10, 30, 60, 120, 240, 360 mg)
Study: 24423149
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg saxagliptin for 6 weeks
Study: 17518968
Drug: Home visits
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home visits for advising mothers about breastfeeding and weaning; Duration: 10 days after birth, monthly up to 6 months, at 8, 10, and 12 months; Based on 'Ten Steps for Healthy Feeding'
Study: 15601310
Drug: Troxerutin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin (50 mg) and Zn gluconate (25 mg)
Study: 15601310
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with 10 mg Zn gluconate
Study: 12489528
Drug: Therapeutic Play
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Play preparation
Study: 12489528
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Therapeutic Play preparation)
Study: 9774209
Drug: 6.8 g/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.8 g/100 ml commercial carbohydrate‐electrolyte (CHO) beverage (39 +/‐ 4 g of CHO)
Study: 8151323
Drug: DTIC 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 800 mg/m2 IV days 1 and 21
Study: 8151323
Drug: DTIC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC plus rIFN alpha 2a 9 mIU IM daily
Study: 24108515
Drug: Crystalloids (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloids (isotonic or hypertonic saline or Ringer lactate solution)
Study: 19630069
Drug: Emotion Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Regulation Training (ERT) plus treatment as usual (TAU)
Study: 11798216
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the WHO analgesic ladder, appropriate opioid dose escalation, use of adjuvant analgesics, and non-pharmacological methods of pain control
Study: 31629060
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (500 μg every 3 weeks)
Study: 30257178
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention (BI) for illicit drug use linked to ASSIST
Study: 16143732
Drug: Telephone-administered supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered supportive emotion-focused therapy (Control)
Study: 11812697
Drug: lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1% (L)
Study: 11812697
Drug: lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine 1% and sodium bicarbonate 8.4% (L+BIC)
Study: 11812697
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution 0.9% (NSS)
Study: 8722349
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + Epo (150 U/kg, from day +1 to +21)
Study: 8722349
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 micrograms/kg, from day +1 up to reaching an ANC > or = 10(9)/1)
Study: 8722349
Drug: Control (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (neither G-CSF nor Epo)
Study: 2060514
Drug: All agents
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All agents (Cefoperazone, Ceftizoxime, Ceftriaxone)
Study: 2060514
Drug: Ceftriaxone (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (once daily vs twice daily)
Study: 2060514
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three agents
Study: 6337428
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) plus placebo four times daily
Study: 27393722
Drug: Variable-time dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-time dosing of basal insulin peglispro (BIL)
Study: 27393722
Drug: Fixed-time dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-time dosing of basal insulin peglispro (BIL)
Study: 23184419
Drug: Potassium binoxalate
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium binoxalate gel (group A, 40 teeth)
Study: 23184419
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser (group B, 40 teeth: 1 W, 10 Hz, 60 s, irradiated twice)
Study: 17268158
Drug: Low-dose milrinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose milrinone (25 microg/kg loading dose, followed by 0.25 microg/kg/min maintenance)
Study: 17268158
Drug: Low-dose milrinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose milrinone